HC Wainwright Analysts Give Cytosorbents Corp (CTSO) a $12.00 Price Target
Several other equities analysts also recently commented on CTSO. B. Riley started coverage on shares of Cytosorbents Corp in a research note on Thursday, October 6th. They set a buy rating and a $11.25 price objective for the company. Maxim Group reaffirmed a buy rating and set a $8.00 price objective on shares of Cytosorbents Corp in a research note on Wednesday, October 5th. Finally, Brean Capital started coverage on shares of Cytosorbents Corp in a research note on Tuesday, October 4th. They set a buy rating and a $24.00 price objective for the company. Five analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average price target of $13.65.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.65 on Tuesday. The stock has a 50 day moving average price of $5.84 and a 200 day moving average price of $4.84. The firm’s market capitalization is $143.72 million. Cytosorbents Corp has a 52 week low of $3.11 and a 52 week high of $8.10.
Cytosorbents Corp (OTCMKTS:CTSO) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $2.18 million. Analysts forecast that Cytosorbents Corp will post ($0.39) EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock worth $2,447,000 after buying an additional 5,446 shares during the last quarter. Raymond James & Associates increased its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock worth $1,477,000 after buying an additional 247,052 shares during the last quarter. Advisor Group Inc. bought a new position in Cytosorbents Corp during the second quarter worth about $1,372,000. Douglass Winthrop Advisors LLC bought a new position in Cytosorbents Corp during the second quarter worth about $321,000. Finally, BlackRock Fund Advisors increased its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock worth $245,000 after buying an additional 15,203 shares during the last quarter.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.